AKT1 and hepatocellular carcinoma: Inhibitors targeting the PI3K/Akt signaling axis and different downstream pathways in HCC are currently undergoing clinical trials.[71] Figure 2 shows the various mechanisms by which quercetin suppresses the proliferation of liver cancer cells.